Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP

ObjectiveIn the Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6–8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detected at a higher rate in women with HIV-1 subtype D than in women with subtype A. Here, we evaluate the rate of NVP resistance mutations in women with subtype C MethodsNVP resistance mutations were detected using the ViroSeq HIV-1 Genotyping System ResultsThe portion of women with any NVP resistance mutation was higher in those with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 012 trial with either subtype A (28/144 [19.4%]; P